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Recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) is associated
with accelerated progression of liver disease, frequently leading to graft loss and early
death. Existing treatment options for severe recurrent HCV infection are limited by sub-
optimal efficacy, poor tolerability, and numerous drug interactions. We provided sofos-
buvir (SOF) and ribavirin (RBV) on a compassionate-use basis to patients with severe
recurrent hepatitis C, including those with fibrosing cholestatic hepatitis (FCH) and
decompensated cirrhosis who had a life expectancy of 1 year or less. All patients were to
receive 24-48 weeks of SOF plus RBV. Investigators could add pegylated interferon to
the regimen at their discretion. Data from the first 104 patients who completed or pre-
maturely discontinued treatment by January 1, 2014 are presented. Of the 104 patients
analyzed, 52 had an early severe recurrence (diagnosed <12 months after LT) and 52
had cirrhosis (diagnosed >12 months after LT). Twelve patients who underwent retrans-
plantation were excluded from our efficacy analysis. Of the 92 patients assessed, 54
(59%) achieved sustained virological response (SVR) at 12 weeks after the end of treat-
ment, with a higher rate (73%; 35 of 48) in patients with early severe recurrence. Of
the 103 patients assessed for clinical outcome, 59 (57%) reported clinical improvement
at the last study visit, 23 (22%) were unchanged, 3 (3%) had a worsened clinical status,
and 13 (13%) died. Overall, 123 serious adverse events (SAEs) occurred in 49 patients
(47%). SAEs associated with hepatic decompensation were the most frequent, with 26
SAEs occurring in 19 patients (18%). Conclusion: SOF and RBV provide high rates of
SVR in patients with severe recurrent HCV, including patients with early severe recur-
rence, FCH, and cirrhosis. (HEPATOLOGY 2015;61:1485-1494)
T
he leading indication for liver transplantation
(LT) in North America and Western Europe is
liver disease resulting from chronic infection
with hepatitis C virus (HCV).1,2 For patients with
detectable serum levels of HCV RNA at time of trans-
plantation, recurrence of HCV infection is immediate
and universal.3,4 Recurrent HCV infection after trans-
plantation is generally aggressive, and progression to
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cirrhosis and decompensation is more rapid than in
patients with HCV who have not been transplanted.5,6
Patients at higher risk of graft loss include those who
develop acute cholestatic hepatitis (ACH), including
fibrosing cholestatic hepatitis (FCH) and those with
early severe recurrence (significant fibrosis F2 during
the first 12 months after LT).2,7 FCH, an especially
severe type of recurrence, is infrequent (approximately
5% of hepatitis C recurrence after LT), but invariably
leads to liver failure in a matter of months.1,8 By the
fifth postoperative year, one third of LT recipients with
HCV infection have either died, experienced allograft
loss, or developed cirrhosis.9 Once decompensation
occurs, prognosis is poor and survival is usually less
than 1 year.10
Treatment options for patients with recurrent HCV
after transplantation are limited. For patients with
severe recurrence, interferon (IFN)-based regimens are
difficult to tolerate and have disappointing efficacy
with hard-to-manage drug interactions.11 Triple-
therapy regimens with protease inhibitors have been
shown to improve efficacy, but exacerbate the side
effects of treatment and are complicated to administer
with immunosuppressive drugs.12 Retransplantation,
which is often the only remaining option, is con-
strained by an ongoing shortage of donor organs and
is associated with long-term outcomes that are signifi-
cantly worse than after primary transplantation.13
Therefore, there is a great need for a more-potent as
well as more-tolerable regimen without drug interac-
tions for LT recipients with recurrent HCV.
Sofosbuvir (SOF) is a potent inhibitor of the HCV
nonstructural 5B polymerase. SOF has been approved
in combination with ribavirin (RBV), with or without
pegylated IFN (Peg-IFN), for treatment of chronic
hepatitis C (CHC) genotypes 1-6.14-16 SOF has pan-
genotypic activity, a high genetic barrier to resistance,
and a favorable safety profile. Most adverse reactions
reported in clinical studies with SOF have been attrib-
utable to the concurrent use of Peg-IFN or RBV.17
SOF plus RBV for up to 48 weeks is indicated for
patients with HCV and hepatocellular carcinoma
(HCC) awaiting LT.14,18 In addition, 24 weeks of
treatment with SOF and RBV resulted in a 70% sus-
tained virological response (SVR) at 12 weeks after the
end of treatment (SVR12) rate in LT recipients with
advanced fibrosis or cirrhosis, the majority of whom
were previous nonresponders to Peg-IFN treatment.19
Treatment guidelines recently issued jointly by the
American Association for the Study of Liver Diseases,
the Infectious Diseases Society of America, and the
European Association for the Study of the Liver
include recommendations for patients who develop
recurrent HCV infection after LT: 12-24 weeks of
SOF and simeprevir (SIM) or daclatasvir (DCV) with
or without RBV for patients with HCV genotype 1
and 24 weeks of SOF and RBV for patients with
HCV genotype 2 or 3.20 There are case reports of the
successful use of SOF and RBV and SOF and DCV in
treating patients with FCH after LT.21-23 To date,
there have been no reports of SOF-based treatment in
large, prospectively assembled cohorts of patients with
FCH and/or severe rapid recurrence with cirrhosis.
We conducted a compassionate-use program in
which SOF and RBV were provided to patients with
aggressive recurrent HCV and no other treatment
options. The aim of this report is to present the avail-
able efficacy and safety data for patients who com-
pleted or prematurely discontinued treatment before
January 1, 2014.
Patients and Methods
Patients. To be eligible for this program, patients
were required to have undergone LT and have a life
expectancy of 1 year or less owing to hepatic failure if
left untreated. This included patients who had ACH,
severe hepatitis C recurrence, and end-stage liver dis-
ease. Individual requests from physicians that included
patient medical history, laboratory values, clinical
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assessments, and liver biopsy reports were submitted to
the sponsor for review and approval. SOF was sup-
plied under approved individual emergency investiga-
tional new drug applications submitted according to
local country regulations by the treating physicians.
Study Design. There was no planned number of
patients or sites. All patients received 400 mg of SOF
daily plus RBV (dosing as determined by the investiga-
tor) for 24 weeks. Treatment could be extended
beyond 24 weeks (up to 48 weeks total) on a case-by-
case basis, subject to approval by the sponsor. Peg-IFN
could be added to SOF plus RBV at the discretion of
the investigator, based on the patient’s medical history
and ability to tolerate the side effects of IFN treat-
ment. The use of colony-stimulating agents and
erythropoiesis-stimulating agents was allowed as clini-
cally indicated. Investigators were requested to collect
safety labs, including complete blood count, compre-
hensive profiles, and international normalized ratio
(INR) values at screening, baseline, and monthly dur-
ing treatment as well as at post-treatment week 4, 12,
and 24. Child-Turcotte-Pugh (CTP) and Model for
End-Stage Liver Disease (MELD) scores were calcu-
lated according to local references and provided by the
investigator at time points requested above. HCV-
RNA testing was done at each site’s local laboratory
and reported by spreadsheets to the sponsor along
with the clinical and laboratory data above. Drug
resistance was not assessed.
Definitions. Patients who received SOF in this
compassionate-use program were divided into two
groups according to their pattern of HCV recurrence:
(1) those with early aggressive recurrent hepatitis dur-
ing the first year after transplantation and (2) those
who had compensated or decompensated liver disease
and were at least 1 year from transplantation.
Patients in the early aggressive recurrent hepatitis
group included patients with FCH, cholestatic hepati-
tis (CH), and early severe recurrence.
For the definition of FCH, we used the following
criteria set forth by the International Liver Transplan-
tation Society (ILTS)3: (1) HCV recurrence must have
occurred more than 1 month (but within 6 months)
post-transplantation; (2) the patient must have serum
bilirubin levels greater than 6 mg/dL; (3) characteristic
histological state with ballooning of hepatocytes pre-
dominantly in the perivenular zone (not necrosis or
fallout), periportal or pericellular/sinusoidal fibrosis,
prominent cholestasis, paucity of inflammation, and
variable degrees of cholangiolar proliferation without
bile duct loss; (4) very high serum HCV-RNA levels;
and (5) absence of surgical biliary complications (nor-
mal cholangiogram) and absence of evidence for
hepatic artery thrombosis. Patients with CH were
those who did not fulfill all the ILTS criteria for FCH,
but had at least elevated levels of serum bilirubin,
gamma-glutamyltransferase (GGT), and alkaline phos-
phatase (ALP), as well as a liver biopsy showing acute
cholestatic injury. Patients with early severe recurrence
were those with significant fibrosis (F2) or increased
hepatic venous pressure gradient (6 mmHg) devel-
oped before the first year after LT.2,7
Patients in the second group included those with
compensated cirrhosis (Metavir F4 by liver biopsy) or
decompensated liver disease (ascites, hepatic encephal-
opathy [HE], variceal bleeding, or jaundice) at least 1
year from transplantation.
Classification of patients was performed on the basis
of a chart review by two of the authors (X.F. and
T.B.S.). Investigators were contacted if biopsy reports
were not conclusive, laboratory data were missing, or
if the narratives were not sufficiently clear to classify
patients.
Study Assessments. Although no formal study vis-
its were planned, investigators were asked to provide
data on safety and efficacy to the sponsor on an
ongoing basis, including laboratory assessments (HCV
RNA, chemistry, hematology, MELD, and CTP scores)
and narratives describing changes from baseline in
patient status at treatment weeks 4, 12, 24, 36, and 48
as wells as post-treatment weeks 4, 12, and 24. Investi-
gators were asked to assess clinical status at the last
study visit. Improvement was defined as a significant
decrease in HE, improvement or disappearance of asci-
tes, or improvement in liver-related laboratory values
as determined by the investigator. Improvement of
ascites was defined as its disappearance or a significant
reduction in the need for diuretic therapy or paracent-
esis. Improvement of HE was defined as its disappear-
ance or a significant reduction in the number of
episodes, as well as a significant reduction of therapy
as determined by the investigator. Serious adverse
events (SAEs) were to be reported by the investigator
to the U.S. Food and Drug Administration or
country-specific regulatory agency and the sponsor.
Statistical Analysis. No sample-size calculations
were performed, and no inferential statistics or statisti-
cal comparisons were planned. The presentation of
efficacy and safety data are descriptive. Categorical var-
iables are depicted as n (%), and quantitative variables
are shown as median (25-75th percentiles). Categorical
variables were compared using the chi-square (v2) or
Fischer’s exact test, and quantitative variables were
compared by the t test or McWhitnney’s test (if
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unpaired data) or by the t test or Wilcoxon’s test (if
paired data), using SPSS software (v 18; SPSS, Inc.,
Chicago, IL).
Results
Patient Disposition
Patient disposition is depicted in Fig. 1. We include
in the safety analysis all 104 patients who had com-
pleted or discontinued treatment by January 1, 2014.
Of these 104 patients, 77% (80 of 104) received SOF
and RBV and 23% (24 of 104) received SOF, RBV,
and Peg-IFN. Of the 104 patients, 82 completed at
least 24 weeks of treatment, 63 with SOF and RBV,
and 19 with SOF, RBV, and Peg-IFN. Three of the
eighty-two patients who completed treatment died, 4
underwent retransplantation after completing treat-
ment (but preceding the 12-week follow-up visit), and
5 were lost to follow-up. Of the 22 patients who did
not complete planned treatment (17 of whom were
receiving SOF and RBV and 5 of whom were receiving
SOF, RBV, and Peg-IFN), 8 underwent liver retrans-
plantation, 10 died, 3 discontinued treatment because
of adverse events (AEs), and 1 was not adherent to
treatment and was a nonresponder. We include in the
efficacy analysis 92 patients, excluding the 12 who
underwent retransplantation before the SVR12
assessment.
Baseline Characteristics
Demographic and clinical characteristics of the 104
patients overall and by subgroups are provided in
Table 1. Fifty-two patients were categorized as having
early severe recurrent hepatitis in the first year after
transplantation and 52 were classified as compensated/
decompensated with cirrrhosis. Overall, most patients
were male (73%) and most had HCV genotype 1
(82%). Median age was 55 (range, 16-76). Mean base-
line bilirubin and INR were elevated, whereas mean
albumin and platelet counts were below normal levels.
Patients with severe recurrent HCV in the first year
after transplantation had significantly higher mean
total bilirubin, alanine aminotransferase/aspartate
Fig. 1. Patient disposition.
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aminotransferase (ALT/AST), ALP, and GGT levels
than the patients with cirrhosis (P< 0.05 in all cases).
Owing to the nature of this compassionate-use pro-
gram, there was no collection of concomitant medica-
tions or immunosuppression.
Efficacy
Overall. The SVR12 rate, excluding patients who
underwent retransplantation (n5 12), was 59% (54 of
92) (Table 2). Patients who received SOF-RBV had an
SVR12 rate of 56% (39 of 70) and those receiving
SOF-Peg-IFN-RBV had an SVR12 rate of 68% (15
of 22; P5 0.3).
Investigators were asked to assess the clinical status
of their patients at the last study visit in relation to
baseline for all who received at least 1 dose of SOF.
Of the 103 patients with available data, 59 (57%)
were categorized as having an improved clinical status,
23 (22%) had unchanged clinical status, and 21
(21%) had worsened clinical status or had died (Table
3; Fig. 2). Overall, liver function tests (including bili-
rubin and INR) improved significantly over time dur-
ing therapy (Fig. 3).
Efficacy in Patients <12 Months Post-Transplan-
tation. The SVR12 rate in patients with early severe
recurrent hepatitis who did not undergo retransplanta-
tion was 73% (35 of 48). Of the 13 patients who did
not achieve SVR12, 6 died, 4 relapsed, 2 were lost to
follow-up, and 1 discontinued because of an SAE. Of
the patients who received SOF1RBV and those that
received SOF1RBV1IFN, 74% (25 of 34) and 71%
(10 of 14), respectively, achieved SVR12. Median dura-
tion of SOF therapy was 24 weeks (range, a single dose
to 48 weeks). RBV was required to be dosed with SOF,
so, although use of RBV was not collected, the sponsor
assumed that the median duration of RBV was the same
as SOF. Among the 11 subjects given Peg-IFN, the
median duration of Peg-IFN was 24 weeks (range, 3-26).
Among the 52 patients with early severe recurrent
hepatitis, 36 (69%) were judged by investigators to
have improved clinical status at the last study visit, 9
(17%) had unchanged clinical status, and 7 (13%)
either worsened or died (Fig. 2).
Levels of total bilirubin, albumin, INR, and MELD
over time for patients with early severe recurrent
Table 1. Baseline Demographic Characteristics of the Entire Cohort and by Time of Diagnosis
(Early Recurrence vs. Established Cirrhosis)
Characteristic Overall (N5 104)
Acute Hepatitis and Early
Severe Recurrence (N5 52)
Compensated and Decompensated
Cirrhosis (N5 52)
Age, years (IQR) 55 (51-60) 54 (50-60) 56 (51-64)
Male, n (%) 76 (73) 39 (75) 37 (71)
Genotype, n (%)
1a 36 (35) 22 (42) 14 (27)
1b 49 (47) 23 (44) 26 (50)
2 1 (1) 1 (2) 0
3 7 (7) 1 (2) 6 (12)
4 7 (7) 5 (10) 2 (4)
>1 4 (4) 0 4 (8)
HCV RNA, log10 IU/mL (IQR) 6.2 (5.3-7.0) 6.7 (5.5-7.5) 5.8 (5.1-6.4)
Months from OLT (IQR)* 16.8 (18-54) 8.4 (4.8-12.7) 53.1 (33.1-92.1)
Bilirubin, mg/dL median (IQR) 3.1 (1.3-9.7) 4.7 (1.5-19.2) 1.9 (1.2-4.8)
Albumin, g/dL median (IQR) 3.1 (2.7-3.5) 3.1 (2.6-3.6) 3.1 (2.7-3.5)
INR median (IQR) 1.3 (1.1-1.6) 1.2 (1.0-1.5) 1.4 (1.2-1.6)
Platelet count 3103/mL median (IQR) 75 (52-119) 91 (59.3-134.5) 69 (50.3-99.3)
ALT, U/L median (IQR) 71.0 (39.3-167.0) 102.0 (38.5-200.8) 60.0 (39.5-101.3)
AST, U/L median (IQR) 124.5 (70.8-210.5) 145.5 (93.5-339.0) 101.0 (62.3-180.0)
ALP, U/L median (IQR) 164.0 (117.5-263.3) 190.0 (124.5) 148.0 (362.5)
GGT, U/L median (IQR) 144.0 (64.0-426.5) 383.0 (121.0-915.5) 112.7 (45-148.0)
Hemoglobin, g/dL median (IQR) 10.9 (9.6-12.5) 10.9 (9.4-12.2) 11.0 (9.8-12.9)
Creatinine, mg/dL median (IQR) 1.1 (0.9-1.4) 1.1 (0.9-1.4) 1.2 (0.9-1.4)
CTP (IQR) 8 (7-10) N/A 8.0 (7-10)
MELD (IQR) 15 (11-21) 16 (10-22) 14 (11-19)
Antiviral regimens used
SOF1RBV alone, n/N (%) 80/104 (77) 36/52 (69) 44/52 (85)
SOF1RBV1Peg-IFN, n/N (%) 24/104 (23) 16/52 (31) 8/52 (15)
Median duration of SOF, weeks (range) 24 (1-56) 24 (1 dose-48) 24 (1-56)
Median duration of Peg-IFN, weeks (range) 24 (3-26) 24 (3-26) 24 (6-24)
*Time from LT to diagnosis was used to characterize patients into groups. However, time of initiation of therapy was counted in the months from transplantation
in this table.
Abbreviation: IQR, interquartile range.
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hepatitis are provided in Fig. 3A. Serum total bilirubin
levels, which are a hallmark of severe cholestatic dis-
ease, decreased significantly from 4.7 to 0.7 g/dL
(84% decline) from baseline to follow-up week 12.
Albumin values increased from 3.1 to 4 g/dL whereas
INR level remained unchanged. Overall median
MELD scores decreased from 16 to 8 (P5 0.001).
Ten patients met the ILTS definition for FCH.
Eight of the ten FCH patients cleared the virus and
were HCV-RNA negative 12 weeks after the end of
treatment and 2 underwent retransplantation. Of the 8
FCH patients who did not undergo retransplantation,
7 were judged to have improved clinically and 1
remained stable at the end of observation. Laboratory
values improved dramatically in this group of patients:
Median bilirubin values at baseline, at weeks 12 and
24 on treatment, and 12 weeks post-treatment were
10, 1.5, 0.86, and 0.9 mg/dL, respectively. The same
figures for GGT were 690, 127, 55, and 30 IU/L,
respectively, and for albumin 3, 3.3, 3.8, and 4.4 g/
dL, respectively.
Efficacy in Patients >12 Months Post-LT. The
SVR12 rate in the 44 patients with cirrhosis who
did not undergo retransplantation was 43% (19 of
44). Of the 25 patients who did not achieve SVR12,
15 relapsed, 7 died, and 3 discontinued treatment
prematurely (2 SAEs and 1 noncompliance). Of the
patients who received SOF and RBV and those who
received SOF, RBV, and Peg-IFN, 43% (16 of 37)
and 43% (3 of 7) achieved SVR12, respectively. The
median duration of SOF dosing was 24 weeks
(range, 1 dose to 56 weeks). In the 8 subjects receiv-
ing Peg-IFN, median duration of IFN therapy was
24 weeks (range, 6-24).
Fig. 2. Clinical outcomes in
all patients and by diagnosis
(early recurrence vs. estab-
lished cirrhosis). Abbreviation:
ESR, erythrocyte sedimentation
rate.
Table 2. Response (HCV RNA <25 IU/mL) During and After Treatment
Overall (N5 104)
Acute Hepatitis and Early
Severe Recurrence (N5 52)
Compensated and Decompensated
Cirrhosis (N5 52)
During treatment, % (n/n) %*
At week 4 56/104 (54) 24/52 (46) 33/51 (65)
At week 12 82/104 (79) 42/50 (84) 40/49 (82)
At week 24 76/96 (73) 38/48 (79) 38/47 (81)
In post-treatment follow-up, n (%)
At week 4 (SVR4) 62/93 (67) 38/48 (79) 24/46 (52)
At week 12 (SVR12) 54/92† (59) 35/48† (73) 19/44† (43)
Virological failure (%)
On-treatment failure 0 0 0
Relapse 19/92 (21) 4/48 (8) 15/44 (34)
Lost to follow-up 2/92 (2) 2/48 (4) 0
Discontinuation because of SAE 3/92 (3) 1/48 (2) 2/44 (5)
Discontinuation because of nonadherence 1/92 (1) 0 1/44 (2)
Death 13/92 (14) 6/48 (13) 7/44 (16)
*HCV RNA <25 IU/mL response during treatment is in patients for whom HCV-RNA results are available.
†Twelve patients underwent LT during the study and were not included in the efficacy analysis; 4 with acute hepatitis and early severe recurrence and 8 with
compensated and decompensated cirrhosis.
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Of the 51 patients in whom investigators assessed
clinical status at the last study visit, 23 (45%) had
clinical improvement, 14 (27%) had unchanged clini-
cal status from baseline, and 14 (27%) worsened or
died.
Levels of total bilirubin, albumin, INR, and MELD
over time are provided in Fig. 3. Between baseline and
follow-up week 12, median total bilirubin values
decreased from 2.0 to 1.1 g/dL (not significant; NS).
Albumin values increased from 3.1 to 3.5 g/dL
(P5 0.042), INR decreased from 1.4 to 1.2 (NS), and
MELD scores decreased from a median of 14 to 10
(NS).
Outcomes in Patients Who Underwent Transplan-
tation. Twelve patients enrolled in the program
underwent LT, either after the completion of treatment
(n5 4) or while on treatment (n5 8). Of the 4 patients
who completed at least 24 weeks of treatment before
transplantation (all of whom received SOF and RBV), 2
achieved SVR12 after transplantation (1 stopped
Fig. 3. Selected labora-
tory tests and scores over
time. (A) Patients with acute
hepatitis and early severe
recurrence (n5 52). (B)
Patients with compensated
and decompensated cirrho-
sis (n5 52). Variables are
depicted as median and
25–75 percentiles. Abbrevia-
tions: EOT, end of treatment;
FU wk, follow-up week.
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treatment at the time of transplantation with HCV RNA
undetectable and 1 achieved SVR at 4 weeks [SVR4]
before transplantation) and 2 had recurrent infection
after transplantation (1 achieved SVR4 before transplan-
tation and 1 underwent transplantation 10 days after the
end of treatment with HCV RNA undetectable).
Of the 8 patients who were transplanted while on
treatment, 6 achieved SVR12 after transplantation. One
of the six patients received 10 weeks of treatment before
transplantation and stopped treatment on the day of
transplant; the other 5 continued treatment into the
post-transplantation period. Duration of treatment
before transplantation for these patients ranged from 1
to 8 weeks, and all 5 continued treatment post-
transplantation for an average of 6 months. Five of
these six patients received SOF and RBV, and 1 received
SOF, Peg-IFN, and RBV. Of the 2 patients who were
transplanted while on treatment and subsequently expe-
rienced post-transplantation recurrence of infection, 1
received treatment with SOF and RBV for 3 weeks
before transplantation and 1 week after transplantation
before stopping because of an AE. The second patient
received 4 weeks of treatment with SOF, Peg-IFN, and
RBV before transplantation and had recurrence of infec-
tion 2 weeks after transplantation.
Safety
Overall, 123 SAEs occurring in 49 patients (47%)
were reported. Not surprisingly, given that this was a
population of patients with progressive liver disease
and a life expectancy <1 year, SAEs associated with
hepatic decompensation were the most numerous,
with 26 SAEs occurring in 19 patients (18%).
Infections and anemia were reported in 17 and 10
patients, respectively, including one report each of pan-
cytopenia, autoimmune hemolytic anemia, aplastic
anemia, and medullary aplasia/bone marrow failure
(BMF). Dose modifications and interruptions were not
captured as part of this program. Nine patients experi-
enced renal failure/dysfunction (6 acute renal failure, 1
acute-on-chronic renal failure, 1 renal insufficiency,
and 1 acute kidney infection).
Among the 24 patients who received Peg-IFN in
addition to SOF and RBV, 5 (21%) developed infec-
tions that were classed as SAEs: 2 patients with ascites
developed spontaneous bacterial peritonitis (1 resolved
and 1 died), 1 patient developed a Staphylococcus aur-
eus infection and died, 1 had sepsis of unknown ori-
gin, which resolved, and 1 developed cytomegalovirus
(CMV) pneumonitis, which subsequently resolved.
For those 80 patients who did not receive Peg-IFN, 14
SAEs of infection in 13 patients (16%) were reported: 5
developed spontaneous bacterial peritonitis (all resolved), 3
developed sepsis (1 resolved and 2 died), 3 developed
CMV infections (2 resolved and 1 died), 1 had pseudo-
membranous colitis (resolved), 1 tuberculosis (resolved),
and 1 developed pleural empyema (died).
Six SAEs in 5 patients (5%) were considered related
to study drug by the investigator: ascites, diabetes,
neutropenia (2), hemophagocytic syndrome, and med-
ullary aplasia/BMF. Eight SAEs led to early treatment
discontinuation in 6 patients (6%); neutropenia (2),
HCC, deep vein thrombosis, renal failure and sepsis,
renal insufficiency, and subcutaneous infection of the
hand. There were no SAE reports of calcineurin inhib-
itor toxicity or rejection.
There were 8 deaths (8%) during treatment or
within 30 days of last dose (the 5 additional deaths
occurred greater than 30 days after the cessation of
treatment during the follow-up period), mainly related
to progression of liver disease, severe infections or sep-
sis, pulmonary conditions, and renal failure.
Discussion
In this compassionate-use program in patients with
severe hepatitis C recurrence after LT, including
patients with FCH and decompensated cirrhosis, 24-
48 weeks of treatment with SOF and RBV with and
without Peg-IFN resulted in SVR12 in a majority of
patients. This population of patients, who have gener-
ally exhausted available treatments and are expected to
die in a matter of months, are in urgent need of new
treatment options besides retransplantation, the bene-
fits of which are generally short-lived without eradica-
tion of HCV. Our findings suggest that SOF plus
RBV may provide a safe, effective salvage treatment
for this population. Though there are ample data
reporting the safety and efficacy of SOF-based antiviral
therapy in patients with cirrhosis, the safety and effi-
cacy in patients with liver failure and decompensated
cirrhosis has not hitherto been reported on in any con-
text. The results of this study are unique in many
respects and have broad implications.
The most important observation in this study is
that SOF-based antiviral therapy is broadly safe and
substantially effective in patients with severe recurrence
Table 3. Clinical Outcomes by Diagnostic Category
Acute Hepatitis and Early
Severe Recurrence (N5 52)
Compensated and
Decompensated
Cirrhosis (N5 51)
Improved (%) 36 (69) 23 (45)
Stable (%) 9 (17) 14 (27)
Worsened/died (%) 7 (13) 14 (27)
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of hepatitis C infection after LT. Because the two
forms of severe HCV recurrence—early severe recur-
rent HCV, including FCH, and cirrhosis as a result of
recurrent chronic disease more than 1 year after trans-
plantation—have somewhat distinct clinical character-
istics, it was interesting to compare outcomes in these
two groups of patients. Early severe recurrent hepatitis
is often associated with rapid progression to death or
graft loss unless HCV replication can be controlled or
eliminated.3 In our study, patients with early recurrent
hepatitis were more likely to achieve SVR12 (73%)
than those with cirrhosis (43%). This finding is some-
what surprising in light of the higher level of immuno-
suppression given to early LT recipients, compared to
stable long-term LT recipients. Furthermore, previous
studies have demonstrated the difficulty of administer-
ing IFN-based therapies to LT recipients early on after
LT.2,24 Interestingly, the kinetics and extent of viral
suppression was similar at week 4 in the early recur-
rent and late recurrent patients in this study (Table 2).
Moreover, a greater proportion of patients with early
recurrent hepatitis showed clinical improvement with
respect to measures of liver-related laboratory values,
ascites, and HE than patients with decompensated cir-
rhosis (69% vs. 45%, respectively). These results sug-
gest that early treatment of patients with recurrent
HCV infection after transplantation may offer an
advantage over waiting until a patient develops
advanced fibrosis. Early fibrosis developing during the
first months after transplantation might be more likely
to regress than established cirrhosis. The pattern of
fibrous tissue deposition at this early stage post-LT is
quite different from that in patients with CHC, where
portal fibrosis expands into the sinusoids. In patients
with established cirrhosis, old fibrous septa contain
high-density fibrillar collagens (I and III) and proteo-
glycans, as well as an increase in extracellular matrix
cross-linking. The latter may indicate greater difficulty
with respect to fibrosis regression.25 Moreover, the
presence of portal hypertension may also be relevant in
fibrosis irreversibility, given that the latter is associated
with an inflammatory state of the endothelium that
activates hepatic stellate cells.26 This may, in part,
explain why hepatic function did not improve in some
patients despite viral clearance, at least during the first
months after SVR. It is possible that a longer follow-
up might be necessary to observe an amelioration in
liver function and clinical outcomes (liver decompensa-
tion episodes). Nevertheless, it is also possible that, at
very late stages of cirrhosis, improvement of liver func-
tion will not occur. In support of this, the use of lami-
vudine rescue therapy in patients with decompensated
HBV cirrhosis and high bilirubin and creatinine levels
was associated with poor short-term outcomes.27 Over-
all, liver function tests improved significantly in both
groups of patients with multiple fold decreases in bili-
rubin in the early recurrent HCV group, increases in
albumin, and decreases in MELD scores.
Although uncommon—occurring in less than 5% of
patients with recurrent hepatitis C—FCH is a formi-
dable clinical challenge in the early post-LT setting.
Therapeutic options for this rapidly progressive and
frequently fatal condition are needed. Several recent
case studies have shown the feasibility of successful
HCV treatment with protease inhibitor regimens, but
the AEs associated with these combinations limit their
use in this setting. Our findings suggest that treatment
of this very aggressive form of hepatitis C with SOF
and RBV may prove life-saving, and that full recovery
of liver function is possible even in patients with very
advanced liver disease. The SVR12 rate of 80% in our
small cohort of patients with FCH is considerably
higher than that reported in previous studies using
IFN-based therapies.28
Although SOF-based therapy was well tolerated in
these very sick patients, including those with MELD
scores as high as 43 and for whom compassionate-use
approval meant that they had no other standard thera-
peutic options, a number of patients died (13%). The
majority of patients who died succumbed to disease
progression and resulting complications. None of the
deaths were attributed to treatment.
The number of patients treated in this
compassionate-use protocol is not sufficiently large to
settle a number of important questions, such as the role
of Peg-IFN, differences in outcome by HCV genotype,
optimal duration of SOF, and factors predictive of treat-
ment success or failure. Moreover, the patient subgroups
were not prespecified at the outset. The approval of
new direct-acting antiviral therapies is likely in the short
and medium term. The impending availability of newer
agents does not diminish the importance of this study,
particularly given that SOF will likely remain a corner-
stone therapy for many patients.
In conclusion, our findings suggest that a 24- to
48-week course of SOF and RBV may be a promising
rescue therapy for LT recipients with severe and refrac-
tory recurrent HCV. Further studies in this population
involving SOF in combination with other antiviral
agents, including SIM, DCV, and ledipasvir are ongoing.
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